Crinetics Pharmaceuticals, INC 10-Q quarterly reports

Crinetics Pharmaceuticals reports strong Q1 2026 results driven by PALSONIFY commercialization, with significant revenue growth and increased R&D investment.

Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, significant R&D pipeline progress, and increased operating losses in its Q3 2025 filing.

Crinetics Pharmaceuticals reports increased losses driven by accelerated R&D and commercialization efforts, while advancing its lead drug candidates Paltusotine and Atumelnant with positive clinical and regulatory updates.

Crinetics Pharmaceuticals announces its Q1 2025 financial results, showcasing ongoing clinical trials and strategic advancements in its endocrine disease and tumor therapeutics pipeline.

Crinetics Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in clinical trials and a recent NDA submission for paltusotine.

Crinetics Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and financial position.

Crinetics Pharmaceuticals reports a significant increase in cash and investment securities to $901 million, driven by recent equity offerings, while advancing its clinical programs for paltusotine and CRN04894.